Shots:
- Tolerance Bio entered into an exclusive license agreement with NeoImmuneTech for the development and commercialization of efineptakin alfa (NT-I7), for certain thymus-related indications in the Americas and Europe. The company also plans to initiate P-II studies evaluating the therapy for enhancement of thymic function
- Under the agreement, Tolerance Bio will advance efineptakin alfa alongside its existing thymus-focused pipeline, including biologic drugs, thymus-targeting mRNA, and thymus cell therapies. NeoImmuneTech is eligible for potential development and sales milestone payments of up to $260M, plus equity consideration and tiered royalties on net sales
- Efineptakin alfa has been evaluated in more than 800 subjects across 15 clinical studies, generating safety, tolerability, pharmacologic, and clinical data supporting further development
Ref: Tolerance Bio | Image: Tolerance Bio | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information connect with us at connect@pharmashots.com
